BERKELEY, Calif., April 21 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President , CEO and Director, will present an overview of the company at the Deutsche Bank 30th Annual Health Care Conference at the Hyatt Regency Hotel in Baltimore, Maryland.
Dr. Dina's presentation will be webcast live at 2:30 pm ET on Tuesday, May 3, 2005. The webcast presentation may be accessed by visiting http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=DVAX&item_id=1015250 where it will also be archived for 30 days following the presentation.
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three initial indications: ragweed allergy immunotherapeutic, currently in a Phase 2/3 clinical trial; a Hepatitis B vaccine, currently in a Phase 2/3 clinical trial; and an asthma immunotherapeutic that has completed a Phase 2 exploratory trial.
SOURCE Dynavax Technologies Corporation
CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications of Dynavax Technologies Corporation, +1-510-665-4630, or firstname.lastname@example.org
Web site: http://www.dynavax.com
04/21/2005 16:00 EDT http://www.prnewswire.com